GENEVA, Switzerland, Aug. 24, 2022 /PRNewswire/ The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR, MedAlliance's novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in the US in May 2022, with enrollment of the first patient occurring in Germany one week after approval. "We are very excited to finally have drug-eluting technology in the US to treat this difficult patient population," commented the trial's Principal Investigator (PI) Dr. Ehrin Armstrong. "We are encouraged by the positive early outcomes with this novel SELUTION SLR Sirolimus Drug Eluting Balloon (DEB) in Europe and Asia. We hope this FDA IDE trial will demonstrate significant benefit for patients who currently have limited treatment options." The aim of the SELUTION4BTK clinical trial is to demonstrate the superior efficacy and equivalent safety of SELUTION SLR compared
GENEVA, Switzerland, Aug. 24, 2022 /PRNewswire/ The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR, MedAlliance's novel
LimFlow Appoints Jenny Gaffney as Vice President, Health Economics and Reimbursement - read this article along with other careers information, tips and advice on BioSpace
LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced